Trial end-point in chronic obstructive pulmonary disease (COPD): Minimal clinically important difference;Studienendpunkte bei der chronisch-obstruktiven lungenerkrankung (COPD): "Minimal clinically important difference"

Pneumologie

Volumn 62, Issue 3, 2008, Pages 149-157

  Gillissen, Adrian ^a   Buhl, R ^b   Kardos, P ^c   Puhan, M ^d   Rabe, K F ^e   Rothe, T ^f   Sauer, R ^f   Welte, T ^g   Worth, H ^h   Menz, G ^f  

^a Robert Koch Klinik   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Maingau Krankenhaus   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Hochgebirgsklinik Davos ^*

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h KLINIKUM FÜRTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID DERIVATIVE; FLUTICASONE; FORMOTEROL; PLACEBO; SALMETEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DYSPNEA; HUMAN; LUNG FUNCTION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERCEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT FAILURE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 41149153867     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996182     Document Type: Review

References (118)

1. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development - a critical appraisal. Br J Clin Pharmacol 1997; 44: 219-225
2. Mannino DM, Watt G, Hole D et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-643
3. Larj MJ, Bleeker ER. Therapeutic responses in asthma and COPD. Corticosteroids Chest 2004; 126: 138S-149S
4. Lapperre TS, Snoeck-Stroband JB, Gosman MM et al. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 499-504
5. Hogg JC, Chu FS, Sin DD et al. Survival after lung volume reduction in chronic obstructive pulmonary disease insights from small airway pathology. Am J Respir Crit Care Med 2007; 176: 454-459
6. Agusti A. Systemic effects of chronic obstructive pulmonary disease. What we know and what we don't know (but should). Proc Am Thorac Soc 2007; 4: 522-525
7. Jones PW, Agusti AGN. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832
8. Mahler DA, Criner GJ. Assessment tools for chronic obstructive pulmonary disease. Do newer metrics allow for disease modification? Proc Am Thorac Soc 2007; 4: 507-511
9. Sloan JA. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. COPD 2005; 2: 57-62
10. Rennard SI. Minimal clincially important difference, clinical perspective: an opinion. COPD 2005; 2: 51-55
11. Schünemann HJ, Guyatt G. Commentary - goodbye M(C)ID ! Hello MID, where do you come from? Health Serv Res 2005; 40: 593-597
12. Jones PW, Aqusti AG. Outcome and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832
13. Jones PW. St. George's respiratory questionnaire: MCID. COPD 2005; 2: 75-79
14. Gross NJ. Outcome measurements in COPD, are we schizophrenic? Chest 2003; 123: 1325-1327
15. Imfeld S, Bloch KE, Weder W et al. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006; 129: 873-878
16. Vestbo J, Prescott E, Almdal TP et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstrucitve pulmonary disease from a random population sample findings from the Coppenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173: 79-83
17. Oga T, Nishimura K, Tsukino M et al. Analysis fo the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Cate Med 2003; 167: 544-549
18. Martinez FJ, Foster G, Curtis JL et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006; 173: 1326-1334
19. Meyer RJ. U.S. regulatory perspective on the minimal clinically important difference in chronic obstructive pulmonary disease. COPD 2005; 2: 47-49
20. Kiley JP, Sri Ram J, Croxton TL et al. Challenges association with estimating minimal clinically important differences in COPD - the NHLBI perspective. COPD 2005; 2: 43-46
21. Schünemann HJ, Puhan M, Goldstein R et al. Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ). COPD 2005; 2: 81-89
22. Schünemann HJ, Griffith L, Jäschke R et al. Evaluation of the minimum important difference for the feeling thermometer and the St. George's respiratory questionnaire in patients with chronic wirflow limitation. J Clin Epidemiol 2003; 56: 1170-1176
23. Mahler DA, Rosiello RA, Harver A et al. Comparison of clincial dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis 1987; 135: 1229-1233
24. Mahler DA, Weinberg DH, Wells CK et al. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758
25. Gillissen A. Lebensqualität, Dyspnoe-Index und Gehtest. In: Guussen A (Hrsg.). Die chronisch-obstruktive Lungenerkrankung. Bremen: Uni-Med Verlag, 2006: 162-178
26. Hajiro T, Nishimura K, Tsukino M et al. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999; 116: 1632-1637
27. Chu CM, Chan VL, Lin AW et al. Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. Thorax 2004; 59: 1020-1025
28. Hajiro T, Nishimura K, Tsukino M et al. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 785-790
29. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224
30. Aaron SD, Vandemheen KL, Clinch JJ et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121: 688-696
31. Mahler DA, Witek JrTJ. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2: 99-103
32. Puhan MA, Behnke M, Frey M et al. Self-administration of interviewer-administration of the German Chronic Respiratory Questionnaire instrument and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes 2004; 8: 1
33. Kaplan RM. The minimal clinically important difference in generic utility-based measures. COPD 2005; 2: 91-97
34. Puhan MA, Soesilo I, Guyatt GH et al. Combining scores from different patient reported outcome measures in meta-analyses: when is it justified? Health Qual Life Outcomes 2006; 4: 94
35. Reardon J, Awad E, Normandin E et al. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 1994; 105: 1046-1052
36. Mahler DA, Faryniarz K, Tomlinson D et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102: 395-401
37. Make B, Casaburi R, Leidy NK. Interpreting results from clinical trials: understanding minimal clinical important differences in COPD outcomes. COPD 2005; 2: 1-5
38. Schonlau M, Mangione-Smith R, Chan KS et al. Evaluation of a quality improvement collaborative in asthma care: does it improve processes and outcomes of care? Ann Fam Med 2005; 3: 198-199
39. Rutishauser C, Sawyer SM, Bowers G. Quality of life assessment in children and adolescents with asthma. Eur Respir J 1998; 12: 486-494
40. Hays RD, Farivar SS, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD 2005; 2: 63-67
41. Jones PW. Quality of life measurement of patients with diseases of the airways. Thorax 1991; 46: 676-682
42. Vogelmeier C, Buhl R, Crieé C-P et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 2007; 61: e1-e40
43. Anzueto A, Sethi S, Martinez FD. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 554-564
44. Seneff MG, Wagner DP, Wagner RP et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852-1857
45. Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272-277
46. Connors AF, Dawson NV, Tomas C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967
47. Miravitlles M, Ferrer M, Pont A et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395
48. Donaldson GC, Seemungal TAR, Patel IS et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbatoins. Eur Respir J 2003; 22: 931-936
49. Donaldson GC, Seemungal TAR, Bhowmik A et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852
50. Gillissen A, Buhl R, Kardos P et al. Management der akuten Exazerbation der chronisch-obstruktiven Lungenerkrankung (COPD). Dtsch Med Wschr 2003; 128: 1721-1727
51. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398s-401s
52. Franciosi LG, Page CP, Celli BR et al. Marker of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19: 189-199
53. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 1-6
54. Calverley PMA, Anderson JA, Celli BR et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789
55. Calverley PMA, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919
56. Jones PW, Willits LR, Burge PS et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary diasase exacerbations. Eur Respir J 2003; 21: 68-73
57. Calverley PMA, Pauwels RA, Vestbo J et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. Am J Respir Crit Care Med 2002; 165: A226
58. Szafranski W, Ramirez A, Menga G et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81
59. Calverley PMA. Minimal clinically important difference - exacerbations of COPD. COPD 2005; 2: 143-148
60. Griffiths TL, Burr ML, Campbell IA et al. Results of 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-368
61. Oostenbrink JB, Rutten-von-Molken MPMH, Al MJ et al. One-year costeffectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-249
62. Kardos P, Wencker M, Glaab T et al. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149
63. Spencer S, Calverley PMA, Burge PS et al. Impact of preventing exacerbations on deterioation of health status in COPD. Eur Respir J 2004; 23: 698-702
64. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 2001; 17: 928-933
65. Sin DD, Anthonisen NR, Soriano JB et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257
66. Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338
67. Wanger J, Clausen JL, Coates A et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-522
68. Stavem K, Aaser E, Sandvik L et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 2005; 25: 618-625
69. Bang KM, Gergen PJ. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993; 103: 536-540
70. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinetgic therapy in chronic obstructive pulmonary diasease. Am J Respir Crit Care Med 1999; 160: 542-549
71. Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968
72. Jensen RL, Teeter JG, England RD et al. Instrument accuracy and reproducibility in measurements of pulmonary function. Chest 2007; 132: 388-395
73. Pellegrino R, Decramer M, Schayck C van et al. Quality control of spirometry: a lesson from the BRONCUS trial. Eur Respir J 2005; 26: 1104-1109
74. GOLD Executive Committee. Global initiative for chronic obstructive lung disease.www.goldcopd.com 2006
75. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998; 114: 1607-1612
76. Calverley PMA, Burge PS, Spencer S et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664
77. 1. The Lung Heath Study. JAMA 1994; 272: 1539-1541
78. Vestbo J, Sørensen T, Lange P et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 355: 1819-1823
79. Burge PS, Calverley PMA, Jones PW et al. Randomised, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. Br Med J 2000; 320: 1297-1303
80. Pauwels RA, Lofdahl C-G, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953
81. Parker CM, Voduc N, Aaron SD et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26: 420-428
82. Quanjer PhH. Standardized lung function testing. Report working party "standardization of lung function tests", European community for coal and steel, Luxembourg. Bull Europ Physiopath Resp 1983; 19: 27-36
83. Cerveri I, Pellegrino R, Dore R et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88: 1989-1995
84. O'Donnell DE, Flüge T, Gerkern F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840
85. O'Donnell DE, Voduc N, Fitzpatrick M et al. Effect of salmeterol on the ventilatory response to exercise in COPD. Eur Respir J 2004; 24: 86-94
86. Celli BR, ZuWallack R, Wang S et al. Improvement in resting inspiratory capacity and hyperinflammation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748
87. Noord JA van, Aumann J, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 124: 1743-1748
88. Cerveri I, Dore R, Corsico A et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004; 125: 1714-1718
89. MacIntyre N, Crapo RO, Viegi G et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735
90. Punjabi NB, Shade D, Patel AM et al. Measurement variability in single-breath diffusing capacity of the lung. Chest 2003; 123: 1082-1089
91. Magnussen H, Goeckenjan G, Köhler D et al. Leitlinien zur Langzeit-Sauerstofftherapie. Pneumologie 2001; 55: 454-464
92. Jones SE, Packham S, Hebden M et al. Domiciliary nocturnal intermittent positive pressure ventilation in patients with respiratory failure due to severe COPD: long-term follow up and effect on survival. Thorax 1998; 53: 495-498
93. Hein H, Rasche K, Wiebel M et al. Empfehlung zur Heim- und Langzeitbeatmung. Med Klinik 2006; 101: 148-152
94. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931
95. Emtner MI, Amardottir HR, Hallin R et al. Walking distance is a predictor of exacerbations in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101: 1037-1040
96. Stulbarg MS, Carrieri-Kohlman V, Demir-Deviren S et al. Exercise training improves outcomes of a dyspnea self-management program. J Cardpulm Rehabil 2002; 22: 109-121
97. Behnke M, Taube C, Kirsten DK et al. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir Med 2000; 94: 1184-1191
98. American Thoracic Society. Guidelines for methacholine and exercise challenge testing-1999. Am J Respit Crit Care Med 2000; 161: 309-329
99. Kirsten DK, Taube C, Lehnigk B et al. Exercise training improves recovery in patients with COPD after an acute exacerbation. Respir Med 1998; 92: 1191-1198
100. European Respiratory Society. Clincial exercise testing with reference to lung diseases: indication, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. Eur Respir J 1997; 10: 2662-2689
101. Jones PW. Health status measurment in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-887
102. Casaburi R. Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD 2005; 2: 131-136
103. Amercian Thoracic Society, American College of Chest Physicians. ATS/ ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-277
104. Palange P, Ward SA, Carlsen K-H et al. ERS task force recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007; 26: 185-209
105. Emtner M, Porszasz J, Burns M et al. Benefits of supplemental oxygen in exercise training in non-hypoxemic COPD patients. Am J Respir Crit Care Med 2003; 168: 1034-1042
106. American Thoracic Society. ATS-Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117
107. Singh SJ, Morgan MDL, Hardman AE et al. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J 1994; 7: 2016-2020
108. Wise RA, Brown CD. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD 2005; 2: 125-129
109. Langley PC. The NICE reference case requirement: implications for drug manufactures and health systems. Pharmacoeconomics 2004; 22: 267-277
110. Landbo C, Prescott E, Langer P et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861
111. Bargon J, Müller U. Malnutrition bei COPD. Pneumologie 2001; 55: 475-480
112. Wouters E. Nutrition and Metabolism in COPD. Chest 2000; 117: 274s-280s
113. Creutzberg EC, Schols AMWJ, Weling-Scheepers CAPM et al. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 745-752
114. Schols AMWJ, Slangen J, Volovics L et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797
115. Wouters EF. Minimal clinically important differences in COPD: body mass index and muscle strength. COPD 2005; 2: 149-155
116. Dal Negro RW, Pomari C, Tognella S et al. Salmeterol & Fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003; 16: 241-246
117. Calverley PMA, Pauwels RA, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456
118. Calverley PMA, Olsson H. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD. Am J Respir Crit Care Med 2003; 167: A319